Cyclerion Therapeutics (CYCN) Competitors $2.33 -0.14 (-5.67%) Closing price 04:00 PM EasternExtended Trading$2.30 -0.03 (-1.33%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. KLTO, KZR, CVKD, DARE, RNTX, MBRX, MIRA, XCUR, RVPH, and PASGShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Klotho Neurosciences (KLTO), Kezar Life Sciences (KZR), Cadrenal Therapeutics (CVKD), Dare Bioscience (DARE), Rein Therapeutics (RNTX), Moleculin Biotech (MBRX), MIRA Pharmaceuticals (MIRA), Exicure (XCUR), Reviva Pharmaceuticals (RVPH), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Its Competitors Klotho Neurosciences Kezar Life Sciences Cadrenal Therapeutics Dare Bioscience Rein Therapeutics Moleculin Biotech MIRA Pharmaceuticals Exicure Reviva Pharmaceuticals Passage Bio Cyclerion Therapeutics (NASDAQ:CYCN) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Do analysts prefer CYCN or KLTO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Klotho Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is CYCN or KLTO more profitable? Klotho Neurosciences has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -89.51%. Cyclerion Therapeutics' return on equity of -22.63% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion Therapeutics-89.51% -22.63% -20.65% Klotho Neurosciences N/A -325.88%-242.15% Which has preferable valuation & earnings, CYCN or KLTO? Cyclerion Therapeutics has higher revenue and earnings than Klotho Neurosciences. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Klotho Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$2.17M3.58-$3.06M-$0.74-3.15Klotho NeurosciencesN/AN/A-$6.15M-$0.45-1.30 Do institutionals and insiders believe in CYCN or KLTO? 75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 20.1% of Klotho Neurosciences shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 26.7% of Klotho Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, CYCN or KLTO? Cyclerion Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Klotho Neurosciences has a beta of 10.05, suggesting that its stock price is 905% more volatile than the S&P 500. Does the media refer more to CYCN or KLTO? In the previous week, Klotho Neurosciences had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 3 mentions for Klotho Neurosciences and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.91 beat Klotho Neurosciences' score of 0.64 indicating that Cyclerion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cyclerion Therapeutics Very Positive Klotho Neurosciences Positive SummaryCyclerion Therapeutics beats Klotho Neurosciences on 7 of the 12 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.78M$3.31B$6.01B$10.23BDividend YieldN/A2.29%5.66%4.69%P/E Ratio-3.1522.1185.3526.57Price / Sales3.58420.49583.22179.26Price / CashN/A47.1938.3262.20Price / Book0.7110.2112.726.53Net Income-$3.06M-$52.40M$3.30B$275.96M7 Day Performance-6.80%0.88%1.05%-1.40%1 Month Performance-1.27%12.35%7.56%5.16%1 Year Performance-12.73%30.13%79.69%31.55% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics2.5039 of 5 stars$2.33-5.7%N/A-3.1%$7.78M$2.17M-3.1530Positive NewsKLTOKlotho Neurosciences1.0648 of 5 stars$0.48-4.2%N/A+19.1%$29.74MN/A-1.08N/AAnalyst ForecastGap UpKZRKezar Life Sciences3.896 of 5 stars$3.90+8.6%$9.00+130.8%-49.1%$28.55M$7M-0.4060Positive NewsAnalyst ForecastHigh Trading VolumeCVKDCadrenal Therapeutics2.5639 of 5 stars$13.83+3.1%$32.00+131.4%+18.7%$28.31MN/A-1.564Analyst ForecastDAREDare Bioscience1.7938 of 5 stars$2.10+0.5%$10.00+376.2%-31.6%$28.31M$10K-0.9830Positive NewsAnalyst ForecastRNTXRein Therapeutics3.1023 of 5 stars$1.15-0.4%$10.00+773.4%N/A$26.69MN/A-0.439News CoveragePositive NewsAnalyst ForecastHigh Trading VolumeMBRXMoleculin Biotech3.0366 of 5 stars$0.53+8.9%$4.00+654.7%-79.8%$26.24MN/A0.0020Analyst ForecastMIRAMIRA Pharmaceuticals0.954 of 5 stars$1.36+2.3%N/A+22.9%$25.94MN/A-2.782Analyst ForecastXCURExicure1.6339 of 5 stars$4.09+4.9%N/A+135.7%$25.85M$500K-1.0550Analyst ForecastRVPHReviva Pharmaceuticals3.6496 of 5 stars$0.37+19.6%$4.86+1,217.7%-28.6%$25.56MN/A-0.575Analyst ForecastGap DownHigh Trading VolumePASGPassage Bio3.61 of 5 stars$8.02-1.4%$75.67+843.0%-23.8%$25.52MN/A-0.44130Analyst ForecastGap Up Related Companies and Tools Related Companies KLTO Competitors KZR Competitors CVKD Competitors DARE Competitors RNTX Competitors MBRX Competitors MIRA Competitors XCUR Competitors RVPH Competitors PASG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs your money positioned for what’s coming?The 7 red flags Wall Street won’t talk aboutAmerican Alternative | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
